Dozens of cancer drugs have been in short supply in recent years as manufacturers closed factories, stopped making products, or halted operations because of quality control problems. Researchers have struggled to quantify the effect shortages have had on patient care, and a new article advances that effort. Amy Billett, HMS associate professor of pediatrics at Dana-Farber Cancer Institute, was one of the authors of the study.
Read full article (subscription required)
